Wojciech Paslawski

Wojciech Paslawski

Besöksadress: BioClinicum J5:20, Akademiska stråket 1, Karolinska universitetssjukhu, 17164 Solna
Postadress: K8 Klinisk neurovetenskap, K8 Neuro Svenningsson, 171 77 Stockholm

Om mig

  • I am working in a Parkinson’s
    disease (PD) field for 11 years. My scientific carrier started with
    biophysical examination of alpha-synuclein (aSN) oligomeric species, which
    are believed to be the most toxic species in PD, and resulted with
    gathering methodological expertise in many scientific techniques. During
    post-doctoral training I extrapolated the pure biophysical protein-protein
    interaction process towards neurotoxicity culprits of aSN. From that point
    my interest were pointed to the basic research
    dedicated to aSN neurotoxicity in cellular models, its interactions with
    other protein and molecules. The post-doctoral training in the
    multidisciplinary team, with ongoing academic and clinical research related
    to PD and other parkinsonian syndromes, extended my research focus and let
    me be involved in projects involving among other the depression
    mechanism and immunological studies. Consequently, during my current work
    as a assistant professor, I am also put part of my research focus into other
    parkinsonian syndromes and the selective vulnerability of neurons
    in PD pathology.
    *Research Support*
    *Source:* Åke Wibergs foundation Research Grant
    *Role:* PI
    *Title:* The role of brain cholesterol and steroids in Parkinson’s disease
    *Source:* The Michael J. Fox Foundation for Parkinson's Research
    *Role:* co-PI
    *Title:* Assessment of apolipoproteins and alpha-synuclein in lipoprotein
    vesicles in cerebrospinal fluid
    *Source:* Karolinska Institute Research Grant
    *Role:* PI
    *Title:* Steroids in neurodegeneration
    *2010-2014 Aarhus University, Department of Molecular Biology and
    Genetics, PhD in Nanoscience*
    *Supervisor: *Daniel Otzen, Professor, Ph.D.
    My PhD project was focused on studying a protein folding and its malfunction
    in amyloid diseases. It engaged the biophysical characterization of protein
    aggregates involved in aforementioned disorders and large screening for
    potential compounds that can inhibit amyloid formation. The second part of
    the project was dedicated to characterization of GlpG membrane protein
    folding and how mutations in protein sequence disturb this process.
    *2005-2010 **Wroclaw University of Technology, Department of
    Chemistry, MSc Eng. in Molecular Biotechnology and Biocatalysis*
    *Supervisor: *Krzysztof Pawlik, Ph.D.
    My early research and Master thesis work was performed in microbiology filed
    and included working with /Streptomyces/ bacteria, the largest
    antibiotic-producing genus, generating antibacterial, antifungal, and
    antiparasitic drugs, and also a wide range of other bioactive compounds. The
    main aim of assignment was characterization of CpkF protein and its role in
    secretion of one of the bioactive compounds by/ S. coelicolor/.


  • Currently I am focused on finding new potential biomarkers (proteins and
    small compounds) for detection early onset of Parkinson’s disease (PD), as
    well as related disorders, and solving mystery of selective vulnerability of
    dopaminergic neurons in PD pathology. For the analysis I am mostly using
    cerebrospinal fluid, but also plasma and other tissues, as it is the
    preferred biosample to address diagnostic and prognostic information related
    to neurodegenerative disorders. This research is important, since PD shares
    symptomatology with several other rare neurodegenerative disorders
    collectively named atypical parkinsonism syndromes (APS). APS include
    corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), multiple
    system atrophy (MSA), vascular parkinsonism and dementia with Lewy bodies
    (DLB). Therefore, in my research I am trying to target challenges caused by
    the overlapping clinical features of PD and APS and find the targets able to
    accurately discriminate between ATP and PD what will be critical for patients
    as the disease progression, and subsequent functional decline, is often more
    rapid in atypical parkinsonism syndromes.
    I am also working with a protein purification and biophysics since beginning
    of my PhD, mainly focusing on α-synuclein protein. I was working on
    characterization of the oligomeric species of α-synuclein, which are
    believed to be the most toxic species in PD. Currently, this part of my work
    is targeted toward identifying new proteins interacting with fibrillar and
    oligomeric α-synuclein.


Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI